Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sage Therapeutics, Inc.    SAGE

SAGE THERAPEUTICS, INC.

(SAGE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The tendency within the weekly time frame is positive above the technical support level at 45.57 USD
Weaknesses
  • Low profitability weakens the company.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • Based on current prices, the company has particularly high valuation levels.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Ratings chart
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
SAGE THERAPEUTICS, INC.10.65%4 157
LONZA GROUP AG56.17%44 950
MODERNA, INC.403.89%39 001
CELLTRION, INC.82.32%36 284
IQVIA HOLDINGS INC.11.32%32 977
SEAGEN INC.44.80%29 684
IMMUNOMEDICS, INC.315.22%20 324
-
INCYTE CORPORATION-6.79%17 682
HANGZHOU TIGERMED CONSULTIN..80.52%15 559
ALNYLAM PHARMACEUTICALS, IN..8.93%14 599
PPD, INC.0.00%11 815
BIO-TECHNE CORPORATION37.95%11 692
PHARMARON BEIJING CO., LTD.86.40%11 345
CHARLES RIVER LABORATORIES ..51.88%11 176
QIAGEN N.V.37.75%10 621
ICON PUBLIC LIMITED COMPANY8.21%9 836
More Results
Financials (USD)
Sales 2020 7,05 M - -
Net income 2020 -482 M - -
Net cash 2020 497 M - -
P/E ratio 2020 -8,91x
Yield 2020 -
Capitalization 4 304 M 4 304 M -
EV / Sales 2020 540x
EV / Sales 2021 236x
Nbr of Employees 675
Free-Float 98,1%
Upcoming event on SAGE THERAPEUTICS, INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes